Share this Page:
In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC).
Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, general fitness of the patient, method of administration of the treatment (oral versus intravenous), and side effect profile, particularly immune-related side effects.
In the following video, Dr Burgess discusses the use of TKIs for poor risk advanced RCC, in particular side effects and how to deal with them:
In the following video, Dr Burgess talks about selecting novel therapy, such as immunotherapy combinations, for the treatment of advanced RCC: